logo
Epic Charter School superintendent resigns after major cuts to staff, facilities

Epic Charter School superintendent resigns after major cuts to staff, facilities

Yahoo09-06-2025
Epic Charter School Superintendent Bart Banfield speaks at a meeting of the school's governing board on Nov. 14 at the 50 Penn Place complex in Oklahoma City. (Photo by Nuria Martinez-Keel/Oklahoma Voice)
OKLAHOMA CITY — Amid mass layoffs of educators, the superintendent of Epic Charter School has resigned.
The virtual charter school announced Monday that Bart Banfield has stepped down after six years in charge. Deputy Superintendent of Instruction Justin Hunt will lead the school in the interim while Epic's governing board searches for a permanent hire.
Banfield led Epic during multiple turbulent periods while the school weathered criminal investigations, a forensic audit, a threat of closure and up-and-down enrollment.
'Bart Banfield's leadership has helped shape our school and strengthen its mission to provide an exceptional, personalized education for students across Oklahoma,' Ginger Casper, president of Epic's school board, said. 'We are grateful for his contributions and wish him continued success in his future endeavors.'
During Banfield's tenure, Epic rapidly grew into the largest school district in Oklahoma in 2020 as families sought online schooling during the COVID-19 pandemic.
Epic, now the state's third-largest district, has experienced declining enrollment ever since, which contributed to pay cuts and layoffs in October. District officials at the time said they overestimated their yearly enrollment by 4,000 students.
This month, the school eliminated 357 teaching and administrative jobs in the latest round of staff cuts. It will close its in-person learning centers in Tulsa and Oklahoma City, as well.
Epic's finances have been under the microscope for several years. The school's co-founders, Ben Harris and David Chaney, were charged in 2022 with embezzlement, racketeering and a litany of other financial crimes stemming from their leadership of Epic.
Harris and Chaney deny allegations that they wrongfully pocketed millions of taxpayer dollars intended for Epic students. Former Epic CFO Josh Brock also was charged in the case and has agreed to testify against the co-founders in exchange for no prison time.
Banfield succeeded Chaney as Epic's superintendent in 2019. He first joined Epic in 2014 as assistant superintendent of instruction.
Harris and Chaney, whose company was paid to manage the school, remained intricately linked with Epic until 2021, when the school's governing board cut ties with them and their business.
While facing threats of closure from the state, Epic's governing board and Banfield's administration implemented financial, organizational and transparency reforms that converted the school into a self-run entity without an outside company involved in its management. Until 2021, Harris and Chaney's company had run and profited from Epic since they founded the school in 2011.
Hunt, who is now interim superintendent, experienced the transition along with Banfield. He was hired in 2017 as managing director of instruction and became deputy superintendent of instruction in 2021.
'Mr. Hunt brings with him a strong commitment to Epic's mission and a deep understanding of our community's needs,' Casper said. 'We are confident that his leadership will ensure continuity and stability as we move forward.'
SUBSCRIBE: GET THE MORNING HEADLINES DELIVERED TO YOUR INBOX
SUPPORT: YOU MAKE OUR WORK POSSIBLE
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Target names longtime insider Michael Fiddelke its next CEO as retailer tries to break sales and stock slump
Target names longtime insider Michael Fiddelke its next CEO as retailer tries to break sales and stock slump

NBC News

time5 minutes ago

  • NBC News

Target names longtime insider Michael Fiddelke its next CEO as retailer tries to break sales and stock slump

Target on Wednesday said that company veteran Michael Fiddelke will become its next CEO at a critical point in its effort to break out of a sales slump and win back Wall Street's favor. Fiddelke, the company's 49-year-old chief operating officer and former chief financial officer, will succeed Brian Cornell effective Feb. 1. Cornell, who took the helm of the cheap chic retailer in 2014, will transition to the role of executive chair on Target's board of directors. The Minneapolis-based retailer made the announcement on the same day it reported fiscal second-quarter results. It topped Wall Street's quarterly sales and earnings expectations, but stuck by a full-year outlook that forecasts another annual sales decline. Target shares dropped about 10% in premarket trading after the company made the CEO announcement and released results. Before Target announced its choice, Wall Street appeared to favor an outsider for the top job. Fiddelke steps into Target's top role as the big-box retailer tries to find its footing and get back to growth. Target's annual sales have been roughly flat for the past four years after the company's sales soared during the Covid pandemic. On a call with reporters, Fiddelke said he is 'stepping in with urgency to rebuild momentum and return to profitable growth.' He laid out three priorities: Reestablishing Target's reputation as a retailer with stylish and unique items, providing a more consistent customer experience and using technology more effectively to operate an efficient business. 'We've built a solid foundation, and we're proud of the many ways that Target is unique in American retail,' he said. 'We also have real work in front of us.' Fiddelke is a 20-year Target veteran. During his decades with the company, he has held leadership roles across merchandising, finance, operations and human resources. He became Target's chief financial officer in late 2019 and stepped into the role of chief operating officer in early 2024. In May, he was tapped to oversee a new effort, the Enterprise Acceleration Office, created to turn around Target's results. Target cut its full-year outlook in May and reiterated that guidance on Wednesday, saying that it expects a low-single-digit percentage point decline in sales this fiscal year. Target's performance has shaken Wall Street's confidence. Shares of the company have tumbled about 60% since their all-time high in 2021. Target's stock had dropped 22% in 2025 alone as of Tuesday's close. Customers, former employees and suppliers told CNBC that the company's best-known traits of eye-catching merchandise, tidy stores and friendly employees have become weaker. The retailer also is facing stiffer competition from rivals including Walmart, contending with cost pressures because of tariffs and dealing with backlash to its reversal of key diversity, equity and inclusion policies. And last week, Ulta Beauty and Target announced they are ending a deal that opened mini beauty shops in nearly a third of Target's stores. The partnership will end in August 2026. Wall Street had favored an outsider for the CEO job, according to a June survey of 51 investors by Mizuho Securities, an equity research firm. About 96% of investors polled favored an external hire for Target's next CEO. Christine Leahy, lead independent director of Target's board of directors, said in a news release that the board chose Fiddelke after 'an extensive external search and assessment of many strong candidates' over several years. 'Michael's tenure gives him unmatched enterprise insight and a base of strong team trust,' she said. 'But what sets him apart is how he combines those strengths with a 'fresh eyes' mindset, challenging the status quo to evolve how the business operates, differentiates and delivers long-term value.' On a call with reporters, Cornell and Fiddelke were asked what they would say to investors who had hoped for Target to hire an outsider who would bring fresh ideas. Fiddelke answered the question. 'I understand this business,' he said. 'I understand what makes Target distinctly unique. And I've seen us at our best, and I've seen us when we're not at our best, and that informs my candid assessment today of where we have work to do as well.' 'But I'll go back to some of what I started with: My number one goal is to get us back to growth.'

Volusia Schools' administrative costs rise, bucking a trend, while enrollment stagnates
Volusia Schools' administrative costs rise, bucking a trend, while enrollment stagnates

Yahoo

time33 minutes ago

  • Yahoo

Volusia Schools' administrative costs rise, bucking a trend, while enrollment stagnates

Volusia County faced stagnant enrollment in 2024, but reported an increase in administrative costs, according to data required by the Educational Accountability Act and distributed by the Florida Department of Education. The administrative spending increase bucks a trend. Over a nine-year trend, costs peaked at 33% in 2020, the year that the COVID-19 epidemic hit, and dropped to 10% in 2023. The number for 2024 was 15%, according to the data. Over the long haul, from 2015 to 2024, the Volusia County School District has seen a $6.5 million increase in administrative costs, when adjusting for inflation, while the number of full-time students dropped by more than 1,800. Schools administrative costs slightly above state average The administrative cost increases were slightly above the state average over nine years, with Volusia ranking 23rd-highest out of 65 counties, compared to the rest of the state. (Gadsden and Jefferson counties were removed due to faulty data.) In the data released by the education department, the number of students enrolled is categorized as "unweighted full-time-equivalent students," which excludes students in charter schools or students who receive vouchers under the Family Empowerment Scholarship and/or McKay Scholarship. So, while Volusia's administrative costs have been growing and outpacing Florida's average, Volusia is only slightly above average in its administrative to instructional spending ratio (31st out of 65 counties), according to an analysis by The News-Journal. For reference, Polk County, which spends the lowest percent on administrative costs relative to instructional costs, spends only about 4.7% of its budget on administration. Franklin County spends the highest percentage on administrative costs relative to instructional costs, spending about 19.2%. Volusia is at about 8.27% Enrollment lagging at Volusia schools Stagnating enrollment isn't unique to Volusia. Statewide, the number of students in Florida's public education system has been static, thanks largely to the expansion of school choice initiatives. In 2001, the Florida Legislature established the Florida Tax Credit Scholarship Program (FTC) to give lower-income families more educational opportunities. Initially, the program required income verification, but Gov. Ron DeSantis removed the financial eligibility requirements in the 2023-2024 school year. Personalized Education Program (PEP) and Family Empowerment Scholarships also led to expanded options for parents. In essence, the programs and other incentives create incentives for parents to seek schooling options outside of public schools. 'Over the course of the years, the legislature has increased the amount of scholarships available to parents in the state, when at its inception it had income verifications,' John Cash, chief of staff for Volusia County Schools, said. 'But then those income verifications are no longer in place, and they have continued to increase the PEP scholarships every year." Cash said that means that as enrollment in the program increases, fewer parents will send their children to public schools, meaning less money will flow into the district's education system. And the census data backs it up. From 2015 to 2023, the school-age population (5 to 17-year-olds) has increased by about 4,500 or 9%, according to the American Community Survey five-year data. Meanwhile, the number of full-time students enrolled in the district decreased by 1.3%. The lower number of enrolled students has already affected the district's budget. 'When it materialized and there was a bigger growth in the scholarship program,' said Todd Seis, the chief financial officer for Volusia County Schools, in a June 24 workshop meeting with the school board. 'We planned for that reduction in we just gave it back to the Department of Education.' So why have costs been increasing when enrollment hasn't? Federal and state laws have forced districts to evolve and, as a result, spend more money. For example, Alyssa's law, which was named after a 14-year-old who died during the Parkland school shooting, forced districts to have panic alert systems. Drills and training for staff also increased costs, according to Seis. Another example is having an internal auditor for districts with over $500 million in annual revenues. Volusia outsources the job to an external firm, but it also led to increased costs. 'The additional requirements established in 2018 have created the need for coordinated support across multiple departments,' Seis wrote in an email to The News-Journal, "including fiscal services, to ensure that internal auditors receive the information they need to complete their reports." This article originally appeared on The Daytona Beach News-Journal: Volusia schools' admin costs rise despite stagnant enrollment Solve the daily Crossword

Nucleus RadioPharma Appoints Former FDA Commissioner Dr. Stephen Hahn as CEO to Scale Patient Access to Radiopharmaceutical Therapies
Nucleus RadioPharma Appoints Former FDA Commissioner Dr. Stephen Hahn as CEO to Scale Patient Access to Radiopharmaceutical Therapies

Business Wire

time34 minutes ago

  • Business Wire

Nucleus RadioPharma Appoints Former FDA Commissioner Dr. Stephen Hahn as CEO to Scale Patient Access to Radiopharmaceutical Therapies

ROCHESTER, Minn.--(BUSINESS WIRE)-- Nucleus RadioPharma, a next-generation contract development and manufacturing organization (CDMO) specializing in radiopharmaceuticals, today announced the appointment of Dr. Stephen M. Hahn as chief executive officer. Hahn's leadership signals Nucleus RadioPharma's urgency in scaling the infrastructure necessary to make minimally invasive, targeted cancer therapies accessible to patients around the world. Hahn joins Nucleus RadioPharma after serving as CEO-partner of Flagship Pioneering and CEO of Harbinger Health since 2021. He served as the 24th U.S. Food and Drug Administration (FDA) commissioner from 2019 to 2021, overseeing both COVID and non-COVID regulatory affairs. Before joining the FDA, he was the chief medical executive at MD Anderson Cancer Center in Houston. The combination of regulatory, clinical and operational knowledge gives him deep insight into how therapies move from clinic to patient. Radiopharmaceuticals represent one of the most promising frontiers in oncology​, offering treatments that are less toxic, less invasive and far more precise in targeting cancer cells. When patients receive these therapies, outcomes improve and quality of life is preserved. However, widespread access to radiopharmaceuticals remains extremely limited​, not due to scientific barriers, but logistical ones. Three interdependent issues drive these supply chain challenges: a fragile and insufficient supply of key isotopes, limited GMP-compliant infrastructure capable of handling a range of medical isotopes and an underdeveloped operational capacity to manage radioactive drugs. 'Radiopharmaceuticals are the next frontier of precision oncology care,' said Hahn. 'But without the infrastructure to deliver these treatments, their impact is fundamentally limited. At Nucleus RadioPharma, we have an extraordinary team that is committed to breaking those barriers. Together, we will scale the systems and infrastructure needed to make these lifesaving therapies available to all who need them.' Under Hahn's leadership, Nucleus RadioPharma is uniquely positioned to tackle these issues, take radiopharmaceuticals to new levels of precision and efficacy and make minimally invasive therapies the new standard for cancer treatment. 'Steve's experience as both a physician treating patients and as a leader at the FDA brings an unparalleled perspective to Nucleus as the company works to build the infrastructure needed to accelerate the widespread availability of radiopharmaceuticals,' said Justin Butler, partner at Eclipse and Nucleus board member. 'His new role is a major indicator to the oncology community that radiopharmaceuticals are the future of precision cancer treatment, and that Nucleus is poised to lead the next era.' Founded in 2022 through a collaboration between Eclipse and Mayo Clinic, Nucleus has raised $72 million in funding to date, including participation from AstraZeneca. The company is building a network of advanced facilities, starting in Mesa, Arizona, and Spring House, Pennsylvania, that integrate research, development and commercial-scale production under one roof, enabling faster, more reliable distribution to clinical trial sites and treatment centers. 'With one of the largest cancer theranostics practices in the world, we have a responsibility to drive continual innovation and develop new targeted diagnostic and therapeutic radioisotopes for our patients,' said Dr. Cheryl Willman, Stephen and Barbara Slaggie executive director for Mayo Clinic Cancer Programs and Mayo Clinic Comprehensive Cancer Center. 'With Steve's exemplary leadership skills and expertise as a cancer physician and scientist, our future could not be brighter.' In his first year as CEO, Hahn will focus on completing the company's GMP readiness at its Rochester, Minnesota, facility, expanding R&D capabilities, launching Nucleus' data platform and forging strategic partnerships. Over the next five years, the company aims to dramatically increase manufacturing capacity and advance initiatives that improve patient access worldwide. For more information on Nucleus RadioPharma, see here. Nucleus RadioPharma is an innovative CDMO dedicated to the development and manufacturing of targeted radiotherapies. With an emphasis on innovation and quality, Nucleus provides an array of services, from formulation and analytical development to regulatory documentation and drug product manufacturing. Its technology platforms are at the forefront of radiopharmaceutical research, designed to advance new therapies through clinical trials to commercialization. Learn more at

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store